PET in the follow-up of differentiated thyroid cancer
- 1 October 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 76 (910), 690-695
- https://doi.org/10.1259/bjr/31538331
Abstract
Fluorine-18-fluorodeoxyglucose (FDG) PET has become an increasingly important functional imaging modality in clinical oncology. This article will focus primarily on the role of FDG PET during treatment and follow-up of thyroid cancer. The major role of FDG PET is in patients with elevated thyroglobulin (Tg) levels where thyroid cancer tissue does not concentrate radioiodine rendering false-negative results on I-131 scanning. FDG PET imaging takes advantage of the increased uptake of FDG in cancer cells and is sensitive (60–94%) to the detection of recurrent or metastatic cancer in patients who have negative radioiodine scans. The specificity (25–90%) of PET imaging is relatively less than its sensitivity because some inflammatory processes avidly accumulate FDG. PET can fail to localize the tumour sites in some patients with well-differentiated thyroid cancer that retain good iodine ability. This can result the well recognized phenomenon of “flip-flop” depending on the differentiation of the thyroid cancer. Several studies have documented the higher accuracy of PET, compared with other imaging modalities in the evaluation of patients with recurrent or metastatic differentiated thyroid cancer. The value of thyroid stimulating hormone stimulation for FDG PET has recently been reported. Therefore, if available, this method should be considered in all patients of differentiated thyroid cancer with suspected recurrence and/or metastasis.Keywords
This publication has 35 references indexed in Scilit:
- Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin StimulationThyroid®, 2002
- Implication of 2-18Fluor-2-Deoxyglucose Positron Emission Tomography in the Follow-Up of Hürthle Cell Thyroid CancerThyroid®, 2002
- Anatomical Distribution and Sclerotic Activity of Bone Metastases from Thyroid Cancer Assessed with F-18 Sodium Fluoride Positron Emission TomographyThyroid®, 2001
- Imaging of Locally Recurrent and Metastatic Thyroid Cancer with Positron Emission TomographyThyroid®, 1999
- Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET ImagingClinical Positron Imaging, 1999
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapyJournal of Clinical Endocrinology & Metabolism, 1993
- Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathyThe Laryngoscope, 1992
- Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinomaCancer, 1984
- SERUM THYROGLOBULIN IN THYROID CANCERThe Lancet, 1981